Vanda Pharmaceuticals(NASDAQ) VNDA

Vanda Pharmaceuticals Inc. makes medicines for sleep and mental health. These treatments help patients manage symptoms and improve their daily lives. Vanda also creates new drugs for rare neurological conditions.

Diverse Treatments for Different Needs

• Mental Health Treatments: Fanapt oral tablets treat schizophrenia, a chronic mental health disorder; also treats manic episodes in bipolar I disorder.
• Sleep Disorder Therapy: HETLIOZ treats non-24-hour sleep-wake disorder, where sleep cycles shift daily, and nighttime disturbances in Smith-Magenis syndrome.
• Immune System Support: PONVORY treats relapsing forms of multiple sclerosis, a condition where the immune system attacks nerves; focus on secondary progressive disease.
• Vomiting Prevention: NEREUS is used to prevent vomiting caused by motion; became commercially available in the U.S. in May 2026.

Recent Moves to Expand

• Launched NEREUS in May 2026 for the prevention of vomiting induced by motion.
• Received FDA approval for BYSANTI in February 2026 for schizophrenia and bipolar I disorder.
• Acquired a global license for Quimilza in 2025 to treat generalized pustular psoriasis.
• Expanded the commercial sales force during 2025 to support new product launches.

Scientific Approach to Drug Development

Vanda uses genetics and genomics to discover and develop new medicines for complex conditions. The company maintains an active pipeline that explores new uses for existing therapies and tests novel candidates for rare diseases.

Financial Performance for 2026

• Fanapt net product sales were $36.0 million in the three-month period ended June 30, 2026, up 23% year over year.
• HETLIOZ net product sales were $5.6 million in the three-month period ended June 30, 2026, down 66% year over year.
• Selling, general and administrative expenses were $71.8 million for the three-month period ended June 30, 2026, up 11% year over year.
• Total cash, cash equivalents, and marketable securities reached $170.0 million as of June 30, 2026.

Bottom Line

Vanda has transformed from a firm with two products to a diversified biopharmaceutical company with five commercial treatments. Its growing pipeline and focus on high unmet medical needs support its long-term strategy in the healthcare sector.